Anticardiolipin antibodies in hemodialysis patients with hepatitis C and their role in fistula failure

Clinical Nephrology

Volumn 72, Issue 3, 2009, Pages 193-198

  Ozmen, S ^a   Danis, R ^a   Akin, D ^a   Batun, S ^a  

^a DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Anticardiolipin antibodies; Hemodialysis vascular access failure

Indexed keywords

CARDIOLIPIN ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRUS RNA;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTERIOVENOUS FISTULA; ARTICLE; BLOOD CHEMISTRY; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SEX DIFFERENCE; SURVIVAL; VIRUS REPLICATION; VIRUS TYPING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTICARDIOLIPIN; ARTERIOVENOUS SHUNT, SURGICAL; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 70350164190     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.2379/CNX06218     Document Type: Article

References (23)

1. Adler S, Szczech L, Qureshi A et al. IgM anticardiolipin antibodies are associated with stenosis of vascular access in hemodialysis patients but do not predict thrombosis. Clin Nephrol. 2001; 56: 428-434.
2. Chan CY, Lee SD, Hwang SJ et al. Quantitative branched DNAassay and genotyping for hepatitis C virus RNA in Chinese patients with acute and chronic hepatitis C. J Infect Dis. 1995; 171: 443-446.
3. Chew SL, Lins RL, Daelemans R et al. Are antiphospholipid antibodies clinically relevant in dialysis patients? Nephrol DialTransplant. 1992; 7: 1194-1198.
4. Chuang FR, Chang HW, Lin CL et al. Anticardiolipin antibody and Taiwanese chronic HD patients with recurrent vascular access thrombosis. Int J Clin Pract. 2005a; 59: 785-790.
5. Chuang FR, Chen TC, Yang CC et al. IgM-anticardiolipin antibody and vascular access thrombosis in chronic hemodialysis patients. Ren Fail. 2005b; 27: 25-30.
6. Danis R, Ozmen S, Akin D et al. Thrombophilias and arteriovenous fistula dysfunction in maintenance hemodialysis. J Thromb Thrombolysis. 2008; May 25, Epub ahead of print.
7. Garcia-Martin F, De Arriba G, Carrascosa T et al. Anticardiolipin antibodies and lupus anticoagulant in endstage renal disease. Nephrol Dial Transplant. 1991; 6: 543-547.
8. Gronhagen-Riska C, Teppo AM, Helentera A et al. Raised concentration of antibodies to cardiolipin in patients receiving dialysis. BMJ. 1990; 300: 1696-1697.
9. Gultekin F, Alagozlu H, Candan F et al. The relationship between anticardiolipin antibodies and vascular access occlusion in patients on hemodialysis. ASAIO J. 2005; 51: 162-164.
10. Harada M, Fujisawa Y, Sakisaka S et al. High prevalence of anticardiolipin antibodies in hepatitis C virus infection: lack of effects on thrombocytopenia and thrombotic complications. J Gastroenterol. 2000; 35: 272-277.
11. Harris EN, Chan JKH, Asherson RA et al. Thrombosis, recurrent fetal loss, and thrombocytopenia: predictive value of anticardiolipin antibody test. Arch Intern Med. 1986; 146: 2153-2156.
12. Haviv YS. Association of anticardiolipin antibodies with vascular access occlusion in hemodialysis patients: cause or effect? Nephron. 2000; 86: 447-454.
13. Knoll GA, Wells PS, Young D et al. Thrombophilia and the risk for hemodialysis vascular access thrombosis. J Am Soc Nephrol. 2005; 16: 1108-1114.
14. Lee CH, Wang IK, Chen TC et al. Anticardiolipin antibodies and vascular access thrombosis in Taiwanese haemodialysis patientswith chronic hepatitis C: a retrospective study. Int J Clin Pract. 2006; 60: 1591-1595.
15. Lee CM, Lu SN, Hung CH et al. Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical implications. Trans R Soc Trop Med Hyg. 2006; 100: 767-774.
16. Ozdemir N, Guz G, Sezer S et al. Anticardiolipin antibodies in hemodialysis patients. Transplant Proc. 1999; 31: 3388-3389.
17. Prakash R, Miller CC, Suki WN. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis. 1995; 26: 347-352.
18. Prieto J, Yuste JR, Beloqui O et al. Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome. Hepatology. 1996; 23: 199-204.
19. Schwab SJ, Harrington JT, Singh A et al. Vascular access for hemodialysis. Kidney Int. 1999; 55: 2078-2090.
20. United States Renal Data System. 2002 Annual Data Report. Bethesda: National Institutes of Health; National Institute of Diabetes and Digestive Diseases. 2002.
21. Valeri A, Joseph R, Radhakrishnan J. A large prospective survey of anticardiolipin antibodies in chronic hemodialysis patients. Clin Nephrol. 1999; 51: 116-121.
22. Yuste JR, Prieto J. Anticardiolipin antibodies in chronic viral hepatitis. Do they have clinical consequences? Eur J Gastroenterol Hepatol. 2003; 15: 717-719.
23. 2-glycoprotein I cofactor or features of antiphospholipid syndrome. Eur J Clin Invest. 2003; 33: 161-168.